|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 1 May 2006, Vol. 107, No. 9, pp. 3455-3462. Prepublished online as a Blood First Edition Paper on December 15, 2005; DOI 10.1182/blood-2005-08-3430.
CLINICAL TRIALS AND OBSERVATIONS
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  P. B. Walter, E. A. Macklin, J. Porter, P. Evans, J. L. Kwiatkowski, E. J. Neufeld, T. Coates, P. J. Giardina, E. Vichinsky, N. Olivieri, et al. Inflammation and oxidant-stress in {beta}-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial Haematologica, June 1, 2008; 93(6): 817 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Vichinsky Oral Iron Chelators and the Treatment of Iron Overload in Pediatric Patients With Chronic Anemia Pediatrics, June 1, 2008; 121(6): 1253 - 1256. [Full Text] [PDF]
|
|
|
|
|
|
E. Angelucci, G. Barosi, C. Camaschella, M. D. Cappellini, M. Cazzola, R. Galanello, M. Marchetti, A. Piga, and S. Tura Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders Haematologica, May 1, 2008; 93(5): 741 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Galanello, A. Piga, M. D. Cappellini, G. L. Forni, A. Zappu, R. Origa, C. Dutreix, R. Belleli, J. M. Ford, G.-J. Riviere, et al. Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen J. Clin. Pharmacol., April 1, 2008; 48(4): 428 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Cohen, E. Glimm, and J. B. Porter Effect of transfusional iron intake on response to chelation therapy in -thalassemia major Blood, January 15, 2008; 111(2): 583 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Masera, C. Rescaldani, M. Azzolini, C. Vimercati, L. Tavecchia, G. Masera, V. De Molfetta, and P. Arpa Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy Haematologica, January 1, 2008; 93(1): e9 - e10. [Full Text] [PDF]
|
|
|
|
|
|
J.-I. Henter and J. Karlen Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia Blood, June 15, 2007; 109(12): 5157 - 5159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rose, O. Ernst, B. Hecquet, P. Maboudou, P. Renom, M. P. Noel, I. Yakoub-Agha, F. Bauters, and J. P. Jouet Quantification by magnetic resonance imaging and liver consequences of post-transfusional iron overload alone in long-term survivors after allogeneic hematopoietic stem cell transplantation Haematologica, June 1, 2007; 92(6): 850 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Stumpf Deferasirox Am. J. Health Syst. Pharm., March 15, 2007; 64(6): 606 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Fabio, F. Minonzio, P. Delbini, A. Bianchi, and M. D. Cappellini Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH) Blood, January 1, 2007; 109(1): 362 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Glickstein, R. B. El, G. Link, W. Breuer, A. M. Konijn, C. Hershko, H. Nick, and Z. I. Cabantchik Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences Blood, November 1, 2006; 108(9): 3195 - 3203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fischer, P. Harmatz, P. Nielsen, and M. D. Cappellini Does liver biopsy overestimate liver iron concentration? Blood, September 1, 2006; 108(5): 1775 - 1776. [Full Text] [PDF]
|
|
|
|
|
|
M. G. Martin, M. O. Arcasoy, and M. D. Cappellini Deferasirox versus deferoxamine. Blood, July 15, 2006; 108(2): 774 - 776. [Full Text] [PDF]
|
|
|
|
|
|
R. Fischer, P. Harmatz, and P. Nielsen Does liver biopsy overestimate liver iron concentration? Blood, July 15, 2006; 108(2): 778 - 778. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Brissot and F. de Bels Current Approaches to the Management of Hemochromatosis Hematology, January 1, 2006; 2006(1): 36 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Cohen New Advances in Iron Chelation Therapy Hematology, January 1, 2006; 2006(1): 42 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Schiffer Clinical Issues in the Management of Patients with Myelodysplasia Hematology, January 1, 2006; 2006(1): 205 - 210. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
-thalassemia
-thalassemia aged 2 years or older. Patients were randomized and received treatment with deferasirox (n = 296) or deferoxamine (n = 290), with dosing of each according to baseline liver iron concentration (LIC). The primary endpoint was maintenance or reduction of LIC; secondary endpoints included safety and tolerability, change in serum ferritin level, and net body iron balance. In both arms, patients with LIC values of 7 mg Fe/g dry weight (dw) or higher had significant and similar dose-dependent reductions in LIC and serum ferritin, and effects on net body iron balance. However, the primary endpoint was not met in the overall population, possibly due to the fact that proportionally lower doses of deferasirox relative to deferoxamine were administered to patients with LIC values less than 7 mg Fe/g dw. The most common adverse events included rash, gastrointestinal disturbances, and mild nonprogressive increases in serum creatinine. No agranulocytosis, arthropathy, or growth failure was associated with deferasirox administration. Deferasirox is a promising once-daily oral therapy for the treatment of transfusional iron overload.